Eligible participants must have the following at both screening and baseline:
* A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months
* Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet
* BSA involvement of ≥0.5% on the face
* F-VASI ≥0.5 and T-VASI ≥3, and
* Either active or stable disease at both screening and baseline
You may not be if
Participants who have other types of vitiligo that are not considered active or stable vitiligo
Currently have active forms of other disorders of pigmentation
Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment
Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved
Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening
Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data
Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve
Clareo Health | A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
